Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Llibre

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|December 15, 2018
Development of darunavir over the entire spectrum of HIV infectionJosep M Llibre
AIDS Reviews|November 27, 2009
First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing betterJosep M Llibre
Antiviral Therapy|November 3, 2010
Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavirJosep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2015
[Resistance profile and genetic barrier of dolutegravir]Josep M Llibre, Bonaventura Clotet
Antiviral Research|June 5, 2016
Abacavir and cardiovascular disease: A critical look at the dataJosep M Llibre, Andrew Hill
AIDS Reviews|July 27, 2012
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatmentJosep M Llibre, Bonaventura Clotet
AIDS Reviews|March 23, 2019
Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer InhibitorsChristian Hoffmann, Josep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2013
Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reductionMiguel A Ramiro, Josep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2009
[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment]Josep M Llibre, Javier Martínez-Picado
AIDS Reviews|May 28, 2013
From TMC114 to darunavir: five years of data on efficacyJosep M Llibre, Arkaitz Imaz, Bonaventura Clotet
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|December 15, 2018
Development of darunavir over the entire spectrum of HIV infectionJosep M Llibre
AIDS Reviews|November 27, 2009
First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing betterJosep M Llibre
Antiviral Therapy|November 3, 2010
Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavirJosep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2015
[Resistance profile and genetic barrier of dolutegravir]Josep M Llibre, Bonaventura Clotet
Antiviral Research|June 5, 2016
Abacavir and cardiovascular disease: A critical look at the dataJosep M Llibre, Andrew Hill
AIDS Reviews|July 27, 2012
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatmentJosep M Llibre, Bonaventura Clotet
AIDS Reviews|March 23, 2019
Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer InhibitorsChristian Hoffmann, Josep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|October 22, 2013
Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reductionMiguel A Ramiro, Josep M Llibre
Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2009
[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment]Josep M Llibre, Javier Martínez-Picado
AIDS Reviews|May 28, 2013
From TMC114 to darunavir: five years of data on efficacyJosep M Llibre, Arkaitz Imaz, Bonaventura Clotet
Pageof 17